Utilidad del levetiracetam como terapia adjunta en pacientes con crisis parciales refractarias

Translated title of the contribution: Use of levetiracetam as adjunctive therapy in patients with refractory partial seizures

Victor J. Del Brutto, Oscar H. Del Brutto

Research output: Contribution to journalArticlepeer-review

Abstract

We conducted a metanalysis of controled trials on the efficacy of levetiracetam (LVT) as add-on therapy for patients with refractory partial seizures. A MEDLINE search revealed five trials comparing the efficacy of different doses of LVT over placebo. Combined data confirmed the efficacy of LVT over placebo for the 50% reduction of seizures during therapy (x2=96.9; p<0,0001; OR=3.73; 95% CI=2.02-4.95), as well as for the complete resolution of seizures (x2=27.01; p<0,0001; OR=7.31; 95% CI=3.08-21.09). Only two trials showed a dose-related (1000 mg/d, 2000 mg/d o 4000 mg/d) efficacy of LVT. This suggest that the initial dose of LVT in these patients should be 1000 mg/d, and that the dose may be increased only in those who do not respond to therapy.

Translated title of the contributionUse of levetiracetam as adjunctive therapy in patients with refractory partial seizures
Original languageSpanish
JournalRevista Ecuatoriana de Neurologia
Volume18
Issue number3
StatePublished - 2009
Externally publishedYes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Use of levetiracetam as adjunctive therapy in patients with refractory partial seizures'. Together they form a unique fingerprint.

Cite this